Aminophylline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aminophylline: From Bronchospasm to Migraine Disorder
One-Sentence Summary
Aminophylline is a methylxanthine derivative with dual pharmacological activity — adenosine receptor antagonism and phosphodiesterase (PDE) inhibition — established as a bronchodilator for asthma, COPD, and apnea of prematurity. The TxGNN model predicts it may be effective for Migraine Disorder by blocking adenosine-mediated intracranial vasodilation and neurogenic inflammation, with 0 registered clinical trials and 6 publications (evidence level L3) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bronchospasm (asthma / COPD / apnea of prematurity) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L3 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Aminophylline is a soluble salt of theophylline and ethylenediamine. Its two primary pharmacological mechanisms are: (1) non-selective adenosine receptor antagonism (blocking A1, A2A, A2B, and A3 subtypes), and (2) non-selective phosphodiesterase (PDE) inhibition, which raises intracellular cAMP and cGMP levels in smooth muscle and neurons. Although formal MOA data could not be retrieved from the system, these mechanisms are well-characterised in the published literature and are directly relevant to the predicted indication.
The scientific case for migraine repurposing is mechanistically coherent. Adenosine — acting via A2A and A2B receptors — promotes intracranial vasodilation and neurogenic inflammation, both of which are central to migraine pathophysiology. Accumulating evidence suggests that migraine attacks may be driven in part by impaired cerebral energy metabolism leading to pathologically elevated extracellular adenosine. By blocking adenosine receptors, aminophylline theoretically interrupts this trigger. In parallel, PDE inhibition modulates downstream cAMP-dependent pathways that regulate CGRP (calcitonin gene-related peptide) release — a validated migraine target already exploited by approved therapies.
The most direct support comes from a 2023 review/case series (Pain Management, PMID 38059379) whose title is specifically "Aminophylline in pain and migraine," describing observational evidence of therapeutic benefit in post-dural puncture headache and pain. A 2022 case report (PMID 34308528) provides indirect confirmation: regadenoson — a selective A2A adenosine receptor agonist — triggered a hemiplegic migraine episode during nuclear cardiology stress testing, and the episode was reversed using methylxanthines including aminophylline. This real-world adenosine–migraine–antagonism chain strengthens the biological plausibility. That said, no prospective clinical trials have yet been conducted, and current evidence does not meet the threshold for clinical implementation.
Clinical Trial Evidence
Currently no related clinical trials registered for Aminophylline in migraine disorder.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38059379 | 2023 | Review / Case Series | Pain Management | Proposes that migraine is driven by elevated adenosine levels and impaired brain energy metabolism; aminophylline (adenosine receptor antagonist) may provide strong relief in pain and post-dural headache, supported by an observational case series |
| 34308528 | 2022 | Case Report | Journal of Nuclear Cardiology | Regadenoson (A2A agonist used during stress MPI) triggered a hemiplegic migraine episode; symptoms reversed by methylxanthines including aminophylline and caffeine — directly demonstrating the adenosine–migraine link |
| 219563 | 1979 | Basic Science | Stroke | Adenosine and adenine compounds markedly dilate feline and human pial arteries in vitro, with the effect absent in extracranial vessels; supports adenosine's selective role in intracranial vascular tone relevant to migraine |
| 7728647 | 1995 | Case Report | Canadian Journal of Cardiology | "Myocardial migraine" case with excessive adenosine effect: dipyridamole (adenosine potentiator) provoked severe pain and ST changes without ischemia; highlights adenosine's role in pain syndromes |
| 14168418 | 1964 | Clinical Report | Aggiornamenti clinicoterapeutici | Early Italian clinical report on pharmacological management of medical headaches; historical context only |
| 5540199 | 1971 | Formulation | The Practitioner | Describes aminophylline suppository formulation; provides context on available routes of administration but has no direct efficacy data for migraine |
Singapore Market Information
Aminophylline (DB01223) is not registered with Singapore's Health Sciences Authority (HSA). There are no active marketing authorizations on record. Any clinical use in Singapore would require compassionate use or importation procedures under applicable HSA regulatory pathways.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic hypothesis — aminophylline's adenosine receptor antagonism blocking migraine-triggering vasodilation — is biologically sound and backed by a directly titled 2023 review and supporting case reports. However, zero prospective clinical trials exist for this indication, the highest-quality evidence is a review/case series (L3), and the drug carries no Singapore registration. The evidence profile is currently insufficient to support clinical implementation or investment without first establishing proof-of-concept trial data.
To proceed, the following is needed:
- A prospective pilot or proof-of-concept RCT evaluating aminophylline (oral or IV) for acute migraine treatment, ideally in a population with high baseline adenosine activity or post-dural puncture headache
- Retrieval of the full safety profile — TFDA/HSA package insert or DrugBank warnings/contraindications — before any clinical protocol can be designed
- Formal MOA documentation from DrugBank to complete the mechanistic dossier
- Determination of the optimal dosing regimen and route of administration for the migraine indication (distinguishing from bronchodilator dosing)
- Comparative positioning against current migraine standard-of-care (triptans, CGRP antagonists) to identify the patient subgroup most likely to benefit
- HSA regulatory pathway assessment for Singapore market entry if Phase 2 data supports advancement
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.